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Abstract 
The current study aimed to explore the lived experience of patients with HCV infection. 
Semi-structured interviews were conducted with seven male participants living with HCV 
and were analysed using Interpretative Phenomenological Analysis (IPA). Two master 
themes were identified: (1) Diagnosis and the search for meaning, and (2) Impact of stigma 
on disclosure. Participants reported fears of contaminating others, feelings of stigma and 
concerns of disclosing the condition to others. Response to diagnosis, stigma and disclosure 
amongst the participants appeared to be interrelated and directly related to locus of blame 
for virus contraction. More specifically, HCV transmission via medical routes led to an 
externalisation of culpability and an openness to disclosure.  Transmission of HCV as a 
direct result of intravenous drug use led to internalised blame and a fear of disclosure. The 
inter- and intra-personal consequences of HCV explored in the current study have potential 
implications for tailoring future psychological therapy and psychoeducation to the specific 
needs of the HCV population. 
 
Keywords 
Hepatitis C Virus (HCV), stigma, disclosure, Interpretative Phenomenological Analysis 
(IPA). 
 
 
 
3 
 
Introduction 
Hepatitis C Virus (HCV) is a blood-borne infection of the liver that affects approximately 
170 million people worldwide (Blach et al., 2017); of which 214,000 cases reside in the 
UK (Public Health England, 2014). Prevalence and incidence of the virus has reduced since 
1990, when blood screening programmes were introduced following a series of 
contaminated blood-transfusions (Sy and Mazen Jamal, 2006). Currently transmission of 
HCV occurs primarily through intravenous drug use (Poynard, 2005). According to the 
most recent report by Public Health England (2017) over 90% of new infections each year 
are identified amongst people who inject illicit drugs. 
     For some individuals, acute HCV infection is a short-term disease that can be 
spontaneously cleared within a matter of weeks following exposure to the virus (Poynard, 
2005). However, the acute form of the virus can, if more severe and untreated, often 
develop into chronic infection. The disease is typically asymptomatic for many years after 
the acute episode, when progression to severe end stage liver failure can occur. Orthotropic 
liver transplantation (OLT) is a life-prolonging option for many patients with Hepatitis C 
infection. However, postoperative recurrence of infection occurs invariably in all HCV-
infected liver transplant patients and constitutes a great burden on patients’ quality of life. 
Of those ‘re-diagnosed’ with HCV, only 10-30% of patients progress to liver cirrhosis, 
developing graft failure. However, once HCV cirrhosis recurs, patients only survive up to 
five years after transplant (Berenguer et al., 2000). To increase survival rates of post-
transplant patients antiviral therapy is used. More recently, HCV treatment has chartered 
new territory with the introduction of direct-acting antivirals (DAAs) that have shown 
efficacy of 81-100% in post-transplant patients (Pungpapong et al., 2015).  
      Despite increased availability and promising results of such treatments, many patients 
report experiences of HCV-related stigma and discrimination (Brener et al., 2015, Harris, 
2009; Zickmund et al., 2003). The aetiology of such stigma is multifaceted but includes 
fear of infectiousness (Fraser and Treloar, 2006), social aversion to illness (Maynard, 
2006), and an association with illicit drug injecting (Cama et al. 2016; Paterson et al, 2006). 
Research has shown that individuals who acquire HCV via medical transmission are 
considered as morally, socially and politically exculpated, whereas those associated with 
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non-medical transmission (injecting drugs) are considered as morally questionable and 
culpable (Duffin, 2005). Compensation claims emphasize the ‘innocent’ status of people 
with HCV acquired through iatrogenic means, while a blame culture exists for those who 
are or have been an injecting drug user (Duffin, 2005; Fraser, 2004). Duffin (2005) 
described this dichotomy as ‘two diseases’ that directly reflect assumptions regarding 
illness-related guilt, innocence and responsibility identified in previous HCV research 
(Fraser and Treloar, 2006). 
Discriminatory reactions can also affect self-perception in those living with HCV 
and the way in which they internalize these reactions. Scambler (2004) described this as 
‘felt stigma’ that refers to the fear of being labelled by others (‘enacted stigma’) or to the 
shame of having a disabling condition. Many studies reveal infectiousness, shame, guilt 
and ostracism as major components of HCV felt-stigma (Conrad et al., 2006; Crocket and 
Gifford, 2004; Lekas, Siegel and Leider, 2011). Participants often refer to themselves as 
infectious or as a ‘potential contaminant’; ‘a leper’ who should be avoided (Harris, 2009). 
Moreover, their self-perception and the embodiment of stigma are facilitated by a lack of 
knowledge about the disease, modes of transmission and risks of HCV in various settings 
(Lekas et al., 2011; Crofts et al., 1997; Paterson et al., 2006). Therefore, raising awareness 
of HCV is not only important in enhancing people’s ability to cope with the illness, but it 
can also determine a willingness to disclose their HCV status to others (Suarez, 2010). 
Fear of stigma may inhibit disclosure of HCV status to others. Given the 
predominantly asymptomatic nature of the illness, HCV can be easily concealed- many 
individuals living with the condition, will, therefore, make a decision to not make ‘visible 
the amorphous nature of the condition’ (Harris, 2009: 44). Disclosure to family, partners 
and medical staff is common (Hopwood & Treloar, 2003), amid fears of transmission 
within families, particularly to partners and children (Lowe and Cotton, 1999). 
Considering that the virus is mainly contracted parenterally by injecting drug use 
(90% of cases worldwide) (Wasley et al., 2008; Hepatitis C Virus Protections Working 
Group, 2006), patients’ fear of transmission may seem irrational. Fear can be to some 
extent justified by the fact that HCV is more transmissible than most of the other viruses, 
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as it can be carried by any blood products and spread via indirect sources (e.g., used razors), 
but epidemiological significance of intrafamilial transmission remains very low (Centers 
of Disease Control and Prevention, 2017). The real reason, however, for the extreme fear 
that causes patients’ social alienation appears to be stigma (both enacted and felt) 
experienced in health services and in people’s own homes. This relates to the lack of 
understanding of the disease (Crocket & Gifford, 2004). In this way discrimination from 
poorly informed health professionals or significant others can erode patients’ self-worth 
and lead to exaggerated fear of virus transmission (Butt et al., 2008). 
The current article contributes to the HCV literature by exploring experiences of 
diagnosis, culpability, stigmatisation and disclosure across a heterogeneous sample of 
patients with HCV. To date, no qualitative studies have specifically addressed the inter-
connection between such experiences nor how they impact the lives of patients (and their 
families) living with the condition. It is important to understand the interconnections as 
they can help predict and understand differences of responsiveness to diagnosis, stigma, 
and disclosure amongst patients. If they are indeed related to locus of blame for virus 
contraction, different psychological interventions should be tailored to meet the individual 
needs of patients with HCV.  
Misconceptions surrounding HCV diagnosis can create not only negative public 
attitudes but also patients’ negative attitudes towards disclosure. Exploring experiences of 
HCV diagnosis may help professionals to facilitate patients’ positive attitudes to disclosure 
and their access to support. Therefore, we aimed to reveal a complex journey through the 
experience of the illness that might have different trajectories for different groups of 
patients with HCV. This study also gives ‘voice’ to a particular group of participants (five 
participants in the current study) that seldom feature within the HCV literature- patients 
who contracted the virus between 1970s-1980s through contaminated blood transfusion.  
 
 
Method 
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Participants 
Seven patients with HCV infection were recruited via a hospital outpatient clinic in 
Scotland. Participants were male and aged between 53 and 68 years (M=57.3yrs). 
Participants were recruited from various geographical locations in Scotland. Participants 
contracted HCV via contaminated blood transfusions (n=5; Gus, Harry, Jimmy, Eric, 
Chris) or injected drug use (n=2; Ted, Steve). Participants reported difficulty in 
ascertaining when they had contracted the virus and in remembering when they were 
diagnosed with it.  However, it is noteworthy that participants who contracted HCV 
through blood transfusion, had undergone medical procedures before 1990- the point at 
which HCV blood screening was introduced in Scotland.    
Procedure and interview 
Ethical approval for the study was sought and obtained from Edinburgh Napier University 
(where the first author was based at that time) and the appropriate regional NHS ethics 
committee.   
Recruitment packs comprising information about the study were either sent directly 
to patients via post (n=18) by a senior research nurse or were distributed by the transplant 
co-ordinators during routine appointments at an out-patient clinic (n=10). The first and last 
authors’ details were provided in order for potential participants to contact the research 
team and indicate their willingness to partake. Participation in this study did not include 
any remuneration.  
Inclusion criteria were that participants should be adults over 18 years of age who 
had diagnosis of HCV and were fluent in the English language. Patients excluded from this 
study were individuals who: (a) had not been seen routinely at the hospital; (b) had been 
currently receiving methadone treatment; (c) had been currently imprisoned; and (e) had 
been deemed by the lead Hepatologist as being too emotionally fragile or possessing a 
current psychosis or other mental health condition.  
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The interviews were conducted by the first author and took place at either a hospital 
(n=5) or in participants’ own homes (n=2). Interviews lasted between 32 and 68 minutes 
(M=50.6) and were recorded on a digital voice recorder. Written consent was obtained 
from the participants prior to the commencement of their interviews. 
A semi-structured interview schedule was prepared prior to the interview and 
included open-ended questions such as ‘Tell me about your experience of HCV diagnosis’ 
and ‘What impact (if at all) has the diagnosis had on your life?’ The topic areas that were 
prepared for the semi-structured interview schedule included: experience of diagnosis, 
instances of stigmatization and approaches to disclosure. The interview schedule was not 
followed in a rigid way, and instead a process of reflecting (e.g., ‘you said there that…’) 
and probing (e.g., ‘tell me more about that’) was adopted. This allowed the participants to 
direct the content of the interview and prioritise issues which they felt were central to the 
topic under investigation. Interviews were then transcribed verbatim and were analysed 
using interpretative phenomenological analysis (IPA). 
Analysis 
Interpretative Phenomenological Analysis (IPA) has been predominantly applied in health 
psychology contexts due to its early concerns with health and illness (Brocki & Wearden, 
2006). This methodology was chosen for this study as it was concerned with the 
interpretation of meaning and the detailed exploration of lived experiences that were 
reflecting authors’ exploratory orientation. IPA foregrounds the experience of the 
individual, and hence provides a ‘voice’ for the lived experiences of a given clinical 
population. This study was also carried out in accordance with principles for validity of 
qualitative research defined by Yardley (2000). Thus, sensitivity to context was 
demonstrated by taking into account existing theoretical and empirical literature and by 
choosing a methodology that was most appropriate to capture the meaning of the 
phenomenon under investigation. Rigour and commitment were demonstrated by the 
author’s personal engagement in the process of recruitment and data collection, and by 
recording data objectively and comprehensively (i.e. voice recording). Authors were 
focused on idiographic engagement in data analysis, illustrating particularities of 
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individual cases by using appropriate quotes, but they did also emphasize the importance 
of shared experiences in formulating the major themes. 
The first author conducted the analysis and the last author independently analysed 
a sample of transcripts. All coding was validated by the second and last author who carried 
out credibility checks on both coding and interpretation. The process of analysis involved 
several key stages as suggested by Smith et al. (2009). These included: 1) reading and re-
reading the transcript, 2) making initial descriptive notes, 3) transforming initial comments 
into emergent themes, 4) looking for connections between the identified themes and 
defining master themes, 5) moving to the next interview and repeating all the steps of the 
analysis, and 6) looking for connections between the cases and developing master themes 
for the whole sample. The extracts presented herein have been selected as they represent 
the most powerful or insightful quotes and capture the very essence of each theme. 
Results 
This article presents two inter-related master themes: (1) Diagnosis and the search for 
meaning; (2) Impact of stigma on disclosure (see Table 1). It is noteworthy that in the 
extracts which follow, (…) represents missing text. Pseudonyms are incorporated 
throughout to ensure participant anonymity and confidentiality. The mode of transmission 
will be indicated against participant pseudonyms, so the reader can better orientate context 
when reading quotes. In efforts to not further stigmatise those who contracted HCV through 
injecting drug use, no acronym will be added to their quotes while ‘BT’ (blood transfusion) 
will be noted against those who contracted HCV in this way. 
 
 
 
 
 
 
Table 1. Master themes and Subthemes. 
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Master themes Subthemes 
1. Diagnosis and the search for meaning 
 
 
2. Impact of stigma on disclosure 
 
Processing diagnosis 
Internalised and externalised blame 
 
Risk of contagion 
Facets of exposure 
 
 
Diagnosis and the search for meaning 
Processing diagnosis. For participants, the lived experience of HCV began at the point of 
diagnosis. For some (Eric, Jimmy, Gus) diagnosis was a highly distressing, life changing 
experience. Others, however (Steve, Ted, Harry), appeared unconcerned or even 
indifferent. The nature of the response varied depending on the medical context of 
examination and diagnosis. All participants of this study were diagnosed when the disease 
was vaguely described and understood, which in a way determined obscure and unclear 
circumstances of medical testing and speculations regarding life expectancy and treatment: 
 
I was in hospital, getting a blood sample taken for something else and I don’t even 
really know why they wanted the blood sample. It had nothing to do with what I 
was in for. Then, about maybe a week or two weeks later, I got a call and I think it 
was a letter, saying that there is an abnormality in my liver (…). I was a bit 
concerned about it, you know, just because it was just suddenly out of the blue. And 
eh… another appointment was made for me. I had a chat and I was told something 
like, “you maybe have got 15 years to live” (laughter). At that time, you know, they 
didn't really know a lot of this. So, it was a bit disconcerting…(Gus) 
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Another participant reported being completely unaware of attending a HCV clinic (Jimmy) 
while awaiting his blood test results: 
 
When they took me in, and when they told me [diagnosis] (…) I had no idea how, 
or where I’d got this. (…) They’re looking at it could’ve been lying dormant for 
years and not – they’ve never actually checked the blood for it and then when I was 
taken unwell, then they kind of looked at me and thought, here, there’s something 
not right. They checked the blood and the Hep C showed up. (Jimmy, BT) 
 
Following the investigation of Jimmy’s symptoms, HCV was perceived to have ‘shown 
up’, stirring from its dormancy like an uninvited, unanticipated stowaway. Its undetected 
existence prior to diagnosis further reinforces the participants’ shock and disbelief at the 
point of diagnosis. Jimmy’s diagnosis reflected a deep sense of shock and disbelief; the 
news appears inconceivable and he instantly is concerned with its aetiology. For other 
participants, uncertainty surrounding their illness evoked a sense of helplessness, 
uncertainty and loss of control: 
 
When I got told I had the virus there was nothing I could do because I’d had it for 
years and years, and I didn’t even know I had it. But once I got the liver transplant, 
I says, “I’ve got that and I’ve still got this virus.”  And that probably preyed on my 
mind a bit, but there’s nothing I could have done about that. [] There’s nothing you 
can do, you know. (Steve) 
 
Thus, at the time, participants found themselves in a position of ‘limbo’- with no 
information around HCV, its progression, prognosis or outcome. A profound loss of control 
ensued, resulting in feelings of helplessness and powerlessness. Many of the participants 
reported being shocked by their diagnosis. There was a troubling sense of uncertainty about 
the ‘dormant’ and unknown nature of HCV. Consequently, in an attempt to understand 
their situation, the participants often sought to identify the source of their HCV. 
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Internalised and externalised blame. Many participants identified clear circumstances 
which they believed led to them acquiring HCV. Two participants (Steve, Ted) reported 
potential exposure events relating to injecting drug use: 
 
When I was 21 I was at a party and there was heroin went around, and I was totally 
naive, I never had taken drugs in my life, and I was 21.  I’d taken a pint, a drink, 
but not much, and it was coming, I never even touched it and I injected it.  I was 21 
years of age, but that was it, I never knew until I was about 51.  So, you’re talking 
about 30 years I never knew I had that. (Steve) 
 
Like Steve’s account, Ted echoed feelings of naivety reporting his drug use as ‘just one of 
those stupid things you have done when you're a kid’. Irrespective of the frequency or 
duration of injecting drug use, both participants expressed some sense of responsibility for 
contracting the virus. There is also a sense of guilt, shame, and genuine regret in Steve’s 
account when he confessed later that injecting drugs was ‘the worst thing’ that he has ever 
done in his life.  
Ted seemed to distance himself from his early life experiences of taking drugs, 
when talking about prioritizing access to treatment.  For Ted, a complex combination of 
inferred agency, diverse transmission routes, the ability to overcome drug addiction and 
the stigma associated with drug use per se all result in an apparent hierarchy of those 
‘deserving’ priority access to treatment: 
People who've caught hepatitis through no fault of their own, should they get treated 
before drug addicts?  Well, my opinion is, it depends how far they are into drugs.  
I wasn't into drugs for a long time.  It wasn't like years I had drugs. These people, 
they’re taking drugs for years and years, they don't want to help themselves. (…) 
But if somebody catches it through blood transfusion, I think they should get it 
before drug addicts, because they've done it. Drug addicts have given it themselves, 
so no, I think people who've caught it accidental, through blood transfer or 
whatever, I do think they should get it before drug addicts, aye, because drug 
addicts have applied it for themselves, self-inflicted. (Ted) 
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Whilst locating himself within this hierarchy of access to treatment, it is interesting to note 
how Ted accomplishes ‘othering’ work through demarcating the ‘deserving’ from the 
‘undeserving’. However, he still does not locate himself within a group of ‘no guilt of their 
own’, which seems to reveal a sense of internalised blame for contracting the virus. Stigma 
is associated with drug use, duration of drug use and inability to overcome addiction. It is 
also interesting to note how the attribution of agency connects the person to the HCV virus; 
amongst people who inject drugs, it is inferred that they have knowingly given themselves 
the virus when in fact they have only knowingly given themselves drugs. Perhaps the 
confusion lies within the agency relating to the needles which have introduced the virus 
into all the participants respective bodies. For those people who had contracted the virus 
through blood transfusion there was relatively little stigma. Five participants (Jimmy, Eric, 
Gus, Harry, Chris) identified undergoing blood transfusion as the likely cause of their 
HCV. These participants reported a sense of anger and injustice at their diagnosis: 
 
I contracted Hep C through contaminated blood given to me for treatment for my 
haemophilia. (…) “You’ve got it.” (…) Somebody gave it to me. I didn’t go out 
there and stick a needle in me… (Eric, BT) 
 
Echoing the earlier points relating to social importance of the attribution of responsibility 
for the movement of the virus from one body to another, Eric’s extract serves to deflect 
any sense of personal culpability. Although not explicit, there is a sense of how he distances 
himself from drug users, denying any role within the moment of transmission and the 
process of injection. In fact, injection is transformed and constructed into a pejorative new 
behaviour ‘sticking needles’: 
 
(…) it shouldn’t have happened, that is basically it. (…) All these thousands of 
people that have been affected by the Hep C they shouldn’t have happened and 
that’s why we are fighting at the moment.” (…) we try to get answers because 
nobody is saying, “It was me that did it.” All we want is somebody to say, “It was 
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the national health’s problem, the government did it and then let’s do something 
about it. (Eric, BT) 
 
Eric’s account is not an individual testimony but an expression of the shared experience of 
injustice. By using ’we’, he seems to unite with all of those who acquired HCV through 
blood transfusion in univocal protest against public silence and dismissal. The repetitive 
use of the personal pronoun (‘we’) might also reinforce the conviction of mutual benefits 
in identifying external sources of blame and responsibility. 
In summary, this section has focused on the participants’ collective and personal 
approaches to diagnosis. The socio-political context of medically acquired HCV appeared 
to influence the external attribution of blame and responsibility, as well as levels of distress 
and uncertainty in response to diagnosis. Conversely, where transmission occurred through 
self-administering drugs, attribution of culpability seemed to be internal and there appeared 
to be less distress associated with the diagnosis itself. 
Impact of stigma on disclosure 
Risk of contagion. An awareness of the infectious nature of HCV led all participants to 
avoid interactions with others. An implicit fear of potentially harming other people, was 
reinforced with stigmatising attitudes which eventually led to a reluctance to disclosing 
their condition to others. Intrusive thoughts of being under surveillance preyed on some 
participants’ minds: 
 
I don’t drink now, but I can go and sit in a pub with them [other people], see if I’ve 
got a glass of juice. I think they’re looking at me as if, what he is doing with a glass, 
he shouldn’t have one.  You know, "he’s sitting there with Hep C, I hope they’re 
going to put that glass in the bin when he’s finished with it sort of thing."  You 
think, is that what’s going through their head, you know.  Aye, as if, you know, 
they’re sitting watching you.  And you see other people about the pub and you 
think, do they know, what’re they staring at me for?  Or what’re they looking over 
here for, you know? It’s a weird, weird feeling, you know. (Jimmy, BT) 
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This exert reflects Jimmy’s own fears and highlights a sense of paranoia. He projects his 
anxieties about being exposed and of being a potential threat to others. The account is 
peppered by a Jimmy’s sense of feeling ‘contaminated’. Similarly, Chris highlights how 
he interprets his increasing social isolation: 
 
(…) it has changed a lot I don’t see people as much, and I never get invited to their 
house and they seem to think that they’ll catch something of me, but I’ve told them 
you cannot catch it. (Chris, BT) 
 
Stigma, therefore, appears to be embedded in preconceptions of HCV as highly contagious 
despite the participant’s best efforts to educate otherwise. Consequently, the expectation 
and eventual experience of social ostracism and rejection created deep emotional turmoil 
for participants.  Chris expressed his wish that all those who discriminated against him, 
could ‘look inside to how my body felt at being excluded’. This was particularly important 
within the family context: 
 
There was a couple of times where my niece was there (…) and wanted something 
for the kids and it was in my mum’s house and I said to her, “Oh I’m going to the 
kitchen I’ll get you it.” And her mother, who is a nurse herself, jumped up and 
shouted, “No, you’ll not bother, I’ll get it.” I thought, that’s a big one, she’s a nurse, 
she should know. (Jimmy, BT) 
 
Here, there is a sense that the imagined contagion fueling stigma in those closest to 
participants, was an even greater blow- ‘a big one’. This extract reveals lack of 
understanding of the disease even amongst the health providers who should not hold these 
kind of misconceptions or irrational fears. 
While for some participants, disrupted and limited interactions with family and 
friends were considered as unwanted consequences of their ‘infectious status’ and a distinct 
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signifier of their exclusion, for others the social separation was their own conscious choice 
and a way of dealing with the situation. Harry and his wife isolated themselves from their 
closest social circle. Harry’s precaution against onwards transmission was manifested in 
his decision to ‘protect’ his relatives and friends from contracting the infection by avoiding 
them: 
So, I told them not to come to our house, not to bring their kids to our house… Even 
my friends stopped coming (…) the first three months I completely ignored all 
people. (Harry, BT) 
 
Facets of exposure. From participant accounts, there was a sense of the moral dimensions 
of disclosure. At times, the participants understood isolating themselves from others as a 
means for protecting other people. There is also another aspect of exposing the ill-self that 
might be anxiety-evoking and result in social withdrawal. There is no failure to disclose, if 
no social interactions take place. In this sense, Jimmy, who disclosed to all his family 
members and friends, prevented himself from dating: 
 
After I was diagnosed I was scared to go into a relationship (…) something I don’t 
think I will, ever have another one, because I don’t think I can turn around and say 
to a female, I’m sorry but I’ve got Hep C, or I’ve had Hep C.  Because I think they’d 
just about turnabout and walk out the door on you.  So, it’s kind of, it’s sad in a way 
knowing that – I don’t think I could get into a relationship knowing that, to have to 
tell somebody that and then knowing they might just walk through the door, reject 
you, and just walk out the door altogether. (Jimmy, BT) 
 
Here, the extent of the negative impact of living with HCV is evident. For others, the 
avoidance of revealing the transmission route brought embarrassment and regret. For 
example, Steve’s decision not to disclose his HCV, even to his loved ones, appeared to 
reflect his shame relating to the single injecting incident from his past. The asymptomatic 
nature of his HCV helped him to disguise his status from his family who were only made 
aware of liver cirrhosis as an official justification for his liver transplantation: 
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None of my family knows. When I found out about the cancer they didn’t know 
from where it was. (Steve) 
 
In contrast, an extremely open approach to disclosure was evident in participants with 
medically acquired HCV that voided any personal responsibility for their illness: 
 
I know a lot of people have a stigma about Hep C but I’ve got no – I’ll tell 
everybody that I’ve got it because it wasn’t my fault. (Eric, BT) 
 
Identifying themselves as ‘innocent victims’, most participants shared their status with 
‘anybody that wanted to know’, especially with those who showed interest and support. 
The position of being an ‘innocent’ recipient of contaminated blood seemed to moderate 
the impact of stigma. Participants who felt that they had nothing to regret or disguise in 
terms of their past, therefore, they were not afraid to disclose their status. Eric seemed to 
contrast himself with those who have a stigma by entering the position of a victim and by 
the act of disclosure. He attempted to do away with HCV stigma by enacting anti-stigma.   
In sum, the act of disclosure appeared as either a means of accessing support or as 
a means of avoiding it. In this sense, some participants tended to disclose their HCV status 
to their family and friends to obtain help they needed, whereas others concealed their 
seropositive status even from their loved ones to protect themselves from rejection and 
judgment.  
Discussion 
This study offers a rich, insightful, experiential account of living with HCV. Semi-
structured interviews afforded participants freedom to respond in their own way and to 
explore anticipated and unanticipated areas of their lived experiences of HCV. The current 
article also contributes to previous HCV literature by exploring diagnosis, culpability, 
stigmatization, and approaches to disclosure across a heterogeneous sample of people with 
17 
 
HCV. The sample included patients who contracted the virus via recreational drug use and 
those who received it through contaminated blood products. Finally, this study raises 
awareness of the psychosocial challenges that reflect HCV patients’ everyday lives. These 
should be central to future interventions with this population. 
 Distinct patterns of responsiveness to diagnosis, stigma and approach to disclosure 
were apparent in relation to HCV transmission routes. Participants who acquired HCV 
through non-medical injecting seemed to report relatively little biographical disruption 
caused by symptomatology or diagnosis. They experienced shame when reflecting on how 
they acquired the virus, but they also seemed to silence remorse by adopting an 
unconcerned view of HCV. In some sense across time, their awareness of the risks of HCV 
associated with sharing injecting equipment consequence became incorporated in their 
identity as former drug users (Olsen et al., 2013). There were continuous agentic 
behaviours that linked their non-medical use of injecting equipment with HCV 
transmission, diagnosis and treatment. Their relatively ‘unconcerned’ attitude could also 
result from the asymptomatic nature of the illness. According to Bury (1982), there is a 
causal relationship between changes in the body and an alteration of the person’s identity. 
Thus, those who experienced no visible or life-interfering symptoms were able to abnegate 
the significance of diagnosis and perceive treatment as more disruptive than diagnosis 
itself. 
Conversely, participants with medically acquired HCV revealed a different 
response to diagnosis that reflected autobiographic uncertainty (Bury, 1982). Feelings of 
fear, shock, anger and helplessness were identified in their excerpts. Strong negative 
reactions to diagnosis were reported and are also reflected within the wider literature 
(Hepworth and Krug, 1999; Tompkins et al., 2005; Suarez, 2010). These feelings are often 
explained in relation to redefining previous identities shaped over years through 
relationships with others (Hepworth & Krug, 1999) or a response to lack of knowledge 
provision (Suarez, 2010). A negative experience of receiving insufficient information and 
help from medical staff over years affected individuals’ sense of control over HCV (Hill et 
al., 2015). 
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The history of injecting drugs was found to be associated with rather ‘unconcerned’ 
responses to diagnosis and internalised blame for viral transmission. Conversely, for 
patients who contracted the virus through blood transfusion or other medical procedures, 
diagnosis was a life-disrupting news that affected both their self-perception and social 
identity. However, unlike the two participants with the history of intravenous drug use, 
these individuals felt no shame or guilt regarding their condition. For participants who 
acquired the virus through IDU, a sense of responsibility and regret accompanied their 
reactions to diagnosis. Young age and associated naivety seemed to offer a justification for 
their risky behaviour from the past, but they seemed to be aware that they were to be blamed 
for contracting the virus.    
A synergy of the lack of knowledge and irrational fear developed in some 
participants into ‘felt’ and ‘enacted stigma’, distinct forms of negative attribution 
recognized in previous literature (Lekas et al., 2011; Tompkins et al., 2005; Scambler, 
2004). The experience of ‘enacted’ and ‘felt stigma’ applied less to populations with 
medically acquired HCV. Unlike participants who contracted the virus through non-
medical injecting, they responded to stigma with directing their strong feelings of blame 
and anger towards external parties. These kinds of responses have the power to preserve 
positive self-identity (Stuenkel and Wong, 2009). They seemed to represent an ‘enacted 
anti-stigma’  
Although, according to Zickmund et al. (2003), stigma affects all diagnosed 
individuals, the current research highlighted that the experience of it can greatly differ 
depending on perceived transmission route, information provision and the source of 
contraction. Combined, these factors appeared to merge and created a foundation of various 
patterns of psycho-social responsiveness to the illness. Two of the patients (Eric, Gus) who 
acquired HCV through blood transfusion and were actively seeking information about the 
disease and treatment, seemed not to be affected by either the felt or enacted stigma. They 
perceived themselves as ‘innocent victims’, not responsible for what happened to them, 
and as such contrasted themselves with the stigmatised population with HCV. Openly 
revealing their health status and actively seeking professional support and information, 
they seemed to demonstrate their anti-stigma approach and cope with illness-related 
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uncertainty. Thus, this study has demonstrated how a framework of uncertainty, that is 
related to the diagnosis of a chronic illness (Bury, 1982), can suddenly shift towards a 
framework of possibilities and certainty when a sense of healthy identity is regained 
through successful battle against stigma and culpability. 
Conversely, all other participants, regardless of the mode of virus transmission, 
described various stigmatizing encounters. Such experiences were intensified by either 
their own or the public’s lack of HCV knowledge. An irrational fear of contagion and 
eroded sense of self in some of the participants stemmed from the lack of understanding of 
the disease observed amongst family members or even health care providers (Crocket and 
Gifford, 2004). Some of the participants, in response to discriminatory episodes that were 
encountered or anticipated, perceived their situation as highly distressing. Fear of social 
alienation led one of the participants to hide his status even from his own family, and 
another one to limit the disclosure only to particularly significant others. This is a common 
reaction towards stigmatisation in HCV and AIDS/HIV populations (Schafer et al., 2005; 
Audet et al., 2013). 
The context, attitudes and beliefs surrounding diagnosis determined participants 
approach to disclosure. A predominant association of HCV with intravenous injecting and 
fear of social discrimination, made the participants with the history of injecting drug use 
either to disclose exclusively to relatives and friends or prevented the disclosure at all. In 
contrast, the participants with medically acquired HCV tended to readily disclose their 
status, emphasizing their role as ‘innocent victims’. Their desire for exposure is unrelated 
to the moral obligation imposed on them by society, as previously recognized by Hepworth 
and Krug (1999), but instead, serves as a means to communicate their own moral 
imperatives despite the experience of injustice and negligence. 
There are a number of limitations of the current research that should be recognized. 
Regarding recruitment, this study had limited accessibility to participants (confined to one 
hospital-based out-patient clinic). Moreover, data herein is exclusive to the HCV 
population in Scotland and required rigid inclusion criteria. This may also have limited the 
pool of potential volunteers. Moreover, the sample of this study consisted of male 
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participants only, therefore, it would be important to extend the considerations of the 
experience of HCV diagnosis, stigma and disclosure to the female patients’ point of view. 
Considering that women are mainly identified as caregivers and are associated with this 
role in society in general, it may be of interest to explore their experience in the opposite 
role. Dunne and Quayle (2001) who explored female patients with HCV showed that 
women might feel guilty and perceive their role within the household as greatly affected 
by their debilitating condition. Thus, the impact of HCV on patients’ quality of life might 
differ between male and female participants. Moreover, five of the participants interviewed 
in this study received the virus through contaminated blood transfusion in the 70s and 80s, 
when HCV diagnostics and treatment were unavailable. The socio-political aspect of their 
reflections might not match experiences of patients diagnosed and treated most recently.  
Despite these limitations, there are a number of clear, important messages from the 
current study. The sense of uncertainty in relation to current and past social interactions 
dominates in participant’s narratives, indicating that there is a definite need for developing 
and delivering new patient-focused approaches in clinical guidance. Problem-solving 
interventions could provide training to people diagnosed with HCV on how to respond to 
diagnosis regardless of the mode of contraction and how to approach various disease-
related issues. These interventions should be carefully tailored to the different needs of 
various groups of patients with HCV and be focused on the ambivalences that characterise 
their cases rather than offer a generalised advice.  
In the new era of direct-acting antivirals (DAAs) that is currently available, patients 
should be thoroughly informed about its efficacy and outcomes for different patient groups 
(i.e. with different HCV genotype or impacted by comorbidities). These information 
sessions regarding new treatment may buffer the impact of diagnosis, giving hopes for 
recovering, or at least minimise HCV-related speculations and uncertainties. 
HCV-focused psychoeducation about HCV-related stigma and transmission risks 
is also needed. It may have a format of interaction among healthcare professionals, patients 
and primary caregivers that would allow all participants to reflect on negative attitudes in 
relation to HCV and bridge the disconnect between patients and health care (Treloar and 
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Hopwood, 2004; Treloar and Rhodes, 2009). Patients’ ability to cope may be enhanced by 
raising awareness of their condition amongst the nearest social and support network. Poor 
knowledge was found to fuel stigma against infected individuals (Butt et al., 2008) and 
stigmatization, in turn, was associated with feelings of social isolation (Hill et al., 2014). 
Thus, the actual infectiousness of HCV needs to be demystified by sharing information and 
establishing regular interpersonal communication. 
Difficulties in accepting the diagnosis by patients with HCV may be alleviated by 
improved access to treatment and by establishing various support groups carefully tailored 
for this heterogeneous group of patients. Furthermore, cognitive-behavioural therapy 
(CBT) can reduce stigma, a sense of self-blame and associated shame. Assigned support 
services may promote assertive approach of patients with HCV in seeking psychological 
help and establishing social networks. However, it is crucial to make sure that the different 
psychosocial approaches to HCV patients aim to meet the individual patient’s needs and 
do not facilitate the ‘guilty-innocent’ distinction based on the HCV transmission routes 
(Fraser and Treloar, 2006). 
Given fearfulness to disclose positive serostatus to others, optional individual or 
family/couple counselling services should be offered to all those recently diagnosed with 
HCV. Physical or emotional symptoms and fear of transmission can be the major factors 
contributing to deteriorating relationships and weakening a circle of support, thus, 
psychological interventions have potential to: 1) resolve communication issues within 
families at the point of diagnosis; 2) strengthen family relationships; and consequently 3) 
improve the support provided. 
Finally, healthcare services should develop a new HCV programme within a 
broader framework of chronic illness which is not only focused on prevention and access 
to health service, but also addresses various aspects of living with chronic conditions, such 
as HCV. Hence, longitudinal findings from future data collection among people living with 
HCV at various points in time is required in order to develop care practices that are tailored 
to the changing needs of HCV patients and to improve their overall quality of life. 
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